Delek US Holdings, Inc. (DK) Analysts See $0.33 EPS; Acelrx Pharmaceuticals (ACRX) Has 0.7 Sentiment

February 15, 2018 - By Moses P. Lee

Analysts expect Delek US Holdings, Inc. (NYSE:DK) to report $0.33 EPS on February, 26.They anticipate $0.77 EPS change or 175.00% from last quarter’s $-0.44 EPS. DK’s profit would be $27.75M giving it 25.58 P/E if the $0.33 EPS is correct. After having $0.81 EPS previously, Delek US Holdings, Inc.’s analysts see -59.26% EPS growth. The stock increased 5.53% or $1.77 during the last trading session, reaching $33.76. About 1.17M shares traded. Delek US Holdings, Inc. (NYSE:DK) has risen 89.96% since February 15, 2017 and is uptrending. It has outperformed by 73.26% the S&P500.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company has market cap of $88.09 million. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain. It currently has negative earnings. The companyÂ’s late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Analysts await AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) to report earnings on March, 1. They expect $-0.21 EPS, 0.00% or $0.00 from last year’s $-0.21 per share. After $-0.28 actual EPS reported by AcelRx Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -25.00% EPS growth.

The stock increased 1.45% or $0.02 during the last trading session, reaching $1.75. About 220,436 shares traded. AcelRx Pharmaceuticals, Inc. (ACRX) has declined 14.24% since February 15, 2017 and is downtrending. It has underperformed by 30.94% the S&P500.

Since January 1, 0001, it had 0 buys, and 1 sale for $53,752 activity.

Geller Family Office Services Llc holds 0.23% of its portfolio in AcelRx Pharmaceuticals, Inc. for 100,000 shares. Perceptive Advisors Llc owns 1.24 million shares or 0.22% of their US portfolio. Moreover, Palo Alto Investors Llc has 0.2% invested in the company for 1.03 million shares. The New York-based Joel Isaacson & Co. Llc has invested 0.06% in the stock. Element Capital Management Llc, a New York-based fund reported 21,540 shares.

Delek US Holdings, Inc. operates as an integrated energy firm that provides petroleum refining and transportation services. The company has market cap of $2.84 billion. The firm operates in two divisions, Refining and Logistics. It has a 18.65 P/E ratio. The Refining segment owns and operates two refineries in Tyler, Texas, and El Dorado, Arkansas; and produces various petroleum products used in transportation and industrial markets.

Investors sentiment decreased to 0.02 in Q3 2017. Its down 0.99, from 1.01 in 2017Q2. It fall, as 105 investors sold Delek US Holdings, Inc. shares while 3 reduced holdings. 0 funds opened positions while 2 raised stakes. 1.51 million shares or 97.20% less from 54.04 million shares in 2017Q2 were reported. Glenmede Na holds 66,000 shares. Alpha Windward Ltd Liability Corporation reported 22,080 shares. Ion Asset Mgmt Ltd invested in 9.85% or 1.21 million shares. Shell Asset Mngmt owns 77,974 shares or 0.04% of their US portfolio. Canada Pension Plan Inv Board invested in 0.01% or 135,500 shares.

Among 20 analysts covering Delek US Holdings (NYSE:DK), 10 have Buy rating, 1 Sell and 9 Hold. Therefore 50% are positive. Delek US Holdings had 65 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Citigroup given on Wednesday, January 24. As per Thursday, September 7, the company rating was maintained by RBC Capital Markets. As per Tuesday, October 24, the company rating was upgraded by Macquarie Research. The firm has “Equal-Weight” rating by given on Monday, October 10. The company was maintained on Friday, September 16 by Piper Jaffray. As per Friday, July 14, the company rating was downgraded by Citigroup. The firm earned “Underperform” rating on Friday, December 8 by Bank of America. As per Wednesday, February 14, the company rating was upgraded by Citigroup. As per Thursday, December 8, the company rating was upgraded by Credit Suisse. RBC Capital Markets maintained Delek US Holdings, Inc. (NYSE:DK) on Wednesday, December 20 with “Buy” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Moses P. Lee

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: